These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 25267563

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series.
    Talotta R, Atzeni F, Batticciotto A, Ditto MC, Gerardi MC, Sarzi-Puttini P.
    J Med Case Rep; 2018 Jun 03; 12(1):154. PubMed ID: 29859543
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.
    Rheumatology (Oxford); 2015 Apr 03; 54(4):601-8. PubMed ID: 25231180
    [Abstract] [Full Text] [Related]

  • 6. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T, Nagano S, Uchino A, Ota T, Akahoshi M, Akashi K.
    Arthritis Res Ther; 2017 Aug 11; 19(1):185. PubMed ID: 28800780
    [Abstract] [Full Text] [Related]

  • 7. Rheumatoid lung nodulosis and osteopathy associated with leflunomide therapy.
    Rozin A, Yigla M, Guralnik L, Keidar Z, Vlodavsky E, Rozenbaum M, Nahir AM, Balbir-Gurman A.
    Clin Rheumatol; 2006 May 11; 25(3):384-8. PubMed ID: 16211338
    [Abstract] [Full Text] [Related]

  • 8. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
    Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ.
    Arthritis Rheum; 2008 Oct 11; 58(10):2968-80. PubMed ID: 18821691
    [Abstract] [Full Text] [Related]

  • 9. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct 11; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 10. Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors.
    Tanaka Y, Takeuchi T, Amano K, Saito K, Hanami K, Nawata M, Fukuyo S, Kameda H, Kaneko Y, Kurasawa T, Nagasawa H, Hoshi D, Sato E, Yamanaka H.
    Mod Rheumatol; 2014 May 11; 24(3):399-404. PubMed ID: 24252045
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry).
    Glace B, Gottenberg JE, Mariette X, Philippe R, Pereira B, Lequerré T, Berthelot JM, Dougados M, Toussirot E, Pham T, Allanore Y, Loeuille D, Euller-Ziegler L, Soubrier M.
    Ann Rheum Dis; 2012 Aug 11; 71(8):1429-31. PubMed ID: 22504557
    [No Abstract] [Full Text] [Related]

  • 12. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N, Betts KA, Messali AJ, Skup M, Garg V.
    Clin Ther; 2017 Aug 11; 39(8):1618-1627. PubMed ID: 28729087
    [Abstract] [Full Text] [Related]

  • 13. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
    Caporali R, Idolazzi L, Bombardieri S, Ferraccioli G, Gerli R, Govoni M, Matucci Cerinic M, Pomponio G, Salaffi F, Tirri R, Benaglio F, Bianchino L, Sarzi-Puttini P, TRUST study investigators..
    Clin Exp Rheumatol; 2017 Aug 11; 35(6):919-928. PubMed ID: 28516890
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Rowell L, Nasmyth-Miller C, Bao M, Wright S, Pope JE.
    Arthritis Care Res (Hoboken); 2014 Nov 11; 66(11):1653-61. PubMed ID: 24942540
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.
    Xue Y, Cohen JM, Wright NA, Merola JF.
    Am J Clin Dermatol; 2016 Apr 11; 17(2):147-62. PubMed ID: 26649439
    [Abstract] [Full Text] [Related]

  • 20. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM, Østergaard M, Bøyesen P, Krogh NS, Thormann A, Tarp U, Poulsen UE, Espesen J, Schlemmer A, Graudal N, Kollerup G, Jensen DV, Madsen OR, Glintborg B, Christensen T, Lindegaard H, Bøhme W, Hansen A, Andersen AR, Hetland ML.
    J Rheumatol; 2014 Dec 11; 41(12):2352-60. PubMed ID: 25274894
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.